Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I):including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R<；sup>；1<；/sup>；, R<；sup>；2<；/sup>；, R<；sup>；3<；/sup>；, R<；sup>；4<；/sup>；, R<；sup>；5<；/sup>；, R<；sup>；6<；/sup>；, R<；sup>；7<；/sup>；, R<；sup>；8<；/sup>；, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
